Literature DB >> 11814399

Depression in Parkinson's disease.

Theresa A Zesiewicz1, Robert A Hauser.   

Abstract

Depression is common in Parkinson's disease (PD), and its identification and treatment are critically important in disease management. Despite depression's high prevalence and major impact on patient quality of life, questions remain regarding its epidemiology and preferred treatment. The authors of this paper summarize available information on the epidemiology of depression in PD, review treatment options, and discuss possible interactions between antidepressants and other agents. This information may help guide clinical treatment and define the need for further studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11814399     DOI: 10.1007/s11920-002-0016-7

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  56 in total

Review 1.  Movement disorders associated with the serotonin selective reuptake inhibitors.

Authors:  R J Leo
Journal:  J Clin Psychiatry       Date:  1996-10       Impact factor: 4.384

2.  Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series.

Authors:  I H Richard; A Maughn; R Kurlan
Journal:  Mov Disord       Date:  1999-01       Impact factor: 10.338

3.  Reversible parkinsonism in a 90-year-old man taking sertraline.

Authors:  D S Schechter; E V Nunes
Journal:  J Clin Psychiatry       Date:  1997-06       Impact factor: 4.384

4.  SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

Authors:  G Dell'Agnello; R Ceravolo; A Nuti; G Bellini; A Piccinni; C D'Avino; L Dell'Osso; U Bonuccelli
Journal:  Clin Neuropharmacol       Date:  2001 Jul-Aug       Impact factor: 1.592

5.  What contributes to depression in Parkinson's disease?

Authors:  A Schrag; M Jahanshahi; N P Quinn
Journal:  Psychol Med       Date:  2001-01       Impact factor: 7.723

6.  Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study.

Authors:  R Cantello; M Gilli; A Riccio; B Bergamasco
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-10       Impact factor: 10.154

7.  Psychiatric disturbances in Parkinson's disease.

Authors:  G G Celesia; W M Wanamaker
Journal:  Dis Nerv Syst       Date:  1972-09

8.  Desipramine in treatment of Parkinson's disease. A placebo-controlled study.

Authors:  L Laitinen
Journal:  Acta Neurol Scand       Date:  1969       Impact factor: 3.209

9.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

10.  Depression in Parkinson's disease.

Authors:  S E Starkstein; T J Preziosi; P L Bolduc; R G Robinson
Journal:  J Nerv Ment Dis       Date:  1990-01       Impact factor: 2.254

View more
  7 in total

Review 1.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

2.  Taste responses in patients with Parkinson's disease.

Authors:  H Sienkiewicz-Jarosz; A Scinska; W Kuran; D Ryglewicz; A Rogowski; E Wrobel; A Korkosz; A Kukwa; W Kostowski; P Bienkowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

Review 3.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

Review 4.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

5.  Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

Authors:  Tultul Nayyar; Michael Bubser; Marcus C Ferguson; M Diana Neely; J Shawn Goodwin; Thomas J Montine; Ariel Y Deutch; Twum A Ansah
Journal:  Eur J Neurosci       Date:  2009-07       Impact factor: 3.386

6.  Emotional response in dopamine D2L receptor-deficient mice.

Authors:  Dubravka Hranilovic; Maja Bucan; Yanyan Wang
Journal:  Behav Brain Res       Date:  2008-09-18       Impact factor: 3.332

7.  Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy.

Authors:  Marco Cosentino; Emilia Martignoni; Donatella Michielotto; Daniela Calandrella; Giulio Riboldazzi; Claudio Pacchetti; Gianmario Frigo; Giuseppe Nappi; Sergio Lecchini
Journal:  BMC Health Serv Res       Date:  2005-03-24       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.